The Lancet Haematology in conversation with Podcast Por The Lancet Group arte de portada

The Lancet Haematology in conversation with

The Lancet Haematology in conversation with

De: The Lancet Group
Escúchala gratis

Lan-Lan Smith, Editor-in-Chief, Emma Cookson, Deputy Editor, and Daniela Marín, Senior Editor at The Lancet Haematology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.

A monthly audio companion to the journal, this podcast covers a broad range of topics, from racial and ethnic disparities in leukaemia survival outcomes to resuscitation with blood products compared with saline, the link between mental health and lymphoma to haemolytic disease in newborns, and more.

© 2025 The Lancet Group Ciencia Ciencias Biológicas Enfermedades Físicas Higiene y Vida Saludable
Episodios
  • Presented at ASH 2025: EPCORE CLL-1 trial on epcoritamab monotherapy for Richter transformation

    Presented at ASH 2025: EPCORE CLL-1 trial on epcoritamab monotherapy for Richter transformation
    Dec 8 2025

    Arnon Kater joins Daniela Marin of The Lancet Haematology to discuss the phase 1b/2 EPCORE CLL-1 trial of epcoritamab monotherapy for Richter transformation, which is being presented at ASH 2025.

    Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00327-8/fulltext

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Más Menos
    14 m
  • ASH 2025 Preview - Expert Roundtable

    ASH 2025 Preview - Expert Roundtable
    Dec 2 2025

    Khaled Musallam, Bethany Samuelson Bannow, Mohamad Mohty, David Sallman, and Anna Sureda join us to share their expectations for the upcoming ASH 2025 congress, to be held from 6 to 9 December 2025 in Orlando, on classical and malignant haematology.

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Más Menos
    22 m
  • Arnon Kater and Sabina Kersting on the HOVON 158/NEXT STEP phase 2 trial testing a new first-line treatment regimen for chronic lymphocytic leukaemia

    Arnon Kater and Sabina Kersting on the HOVON 158/NEXT STEP phase 2 trial testing a new first-line treatment regimen for chronic lymphocytic leukaemia
    Dec 1 2025

    Professor Arnon Kater and Dr Sabina Kersting join us to discuss the results of their phase 2 trial testing a new first-line treatment regimen in chronic lymphocytic leukaemia: fixed-duration ibrutinib–venetoclax followed by MRD-guided ibrutinib–obinutuzumab intensification.

    Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00288-1/fulltext

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Más Menos
    24 m
Todavía no hay opiniones